AUPHAurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc. (AUPH) sells specialty pharmaceuticals, primarily focused on treating chronic kidney disease and other inflammatory conditions. The next catalyst is Feb 25, 2027 — Q4 2026 Earnings Release, which will test the company’s ability to sustain revenue growth and margin expansion amid ongoing formulary access challenges and competitive pressures.
- Revenue reached $318.09M in the latest reported period, with a 5.0% YoY increase.
- Net margin (TTM) stands at 44.3%, reflecting strong profitability.
- Shareholders’ equity is $581.33M, with diluted EPS of $0.23.
The Read
Aurinia's stock mixed after a Q4 2025 beat and softer guidance, remained flat at Investor Day with no new catalysts, beat again in Q1 2026 but drifted lower, surged 11.
The schedule
- Thu25Feb
The earnings release will test whether Aurinia can deliver consistent revenue and margin guidance, especially after the last print where the guidance cut led to a bearish move. The focus will be on the Q4 revenue and the forward-looking commentary on the pipeline.
- Fri5Mar
The news event will test the company's ability to generate positive sentiment around its pipeline and formulary updates, which could influence product mix and revenue expectations. The outcome will depend on the clarity and strength of the messaging around key therapeutic areas.
- Thu6May
This release will test the company's ability to sustain revenue growth and maintain margin expansion, especially with the recent formulary updates. The last print's mixed results on product mix will be a key differentiator.
- Fri9Jul
This event will test the company's ability to sustain investor confidence following recent formulary updates and pipeline progress. The focus will be on the clarity of the messaging around key therapeutic areas and potential market expansion.
- Thu5Aug
The earnings release will test the company's ability to maintain momentum in revenue and cash flow, especially with the recent pipeline updates. The last print's mixed results on cash flow will be a key differentiator.
- Tue2Nov
This release will test the company's ability to deliver strong revenue and margin growth, especially with the recent formulary updates. The last print's mixed results on product mix will be a key differentiator.
Past
- Tue10Nov
Actual outcome: Mixed
The company met EPS estimates with no beat or miss, but guidance remained cautious due to ongoing formulary access challenges and regulatory headwinds. The stock remained flat as investors focused on the lack of progress in key drug launches and pipeline advancements, which failed to align with the bull case assumptions. The price did not reach the bull target or fall below the bear floor, reflecting uncertainty around the company's ability to overcome headwinds.
This earnings report will test the company's ability to meet revenue and EPS guidance amid ongoing formulary access challenges and regulatory headwinds. The outcome will also reflect the progress of key drug launches and pipeline advancements.
- Mon9Nov
Actual outcome: Bull · $15.73 at outcome
The stock closed above the bull target of $15.28, reflecting strong investor confidence following positive news on formulary access and a strategic partnership announcement. Despite a short-term dip, the long-term outlook improved due to these developments, driving the price higher.
This event could involve updates on formulary access, regulatory filings, or strategic partnerships that may influence near-term valuation.
- Thu6Aug
Actual outcome: Bear · $15.18 at outcome
Although Aurinia Pharmaceuticals posted a Q2 earnings beat with EPS of $0.28 surpassing estimates, the stock declined 5.9% following the report. The sell-off was driven by underlying concerns regarding the company's pipeline, specifically potential upcoming challenges to Lupkynis's market exclusivity and a lack of clear development timelines for its candidate aritinercept.
- Wed1Jul
Actual outcome: Bull · $16.10 at outcome
Price reached or exceeded bull target ($16.00) at outcome date.
- Thu7May
Actual outcome: Mixed · $15.60 at outcome
Aurinia reported a first-quarter earnings and revenue beat, posting EPS of $0.25 against consensus estimates of $0.18. Despite the headline beat, the stock drifted lower toward the bear floor by late May, indicating that the results lacked the robust guidance or accelerated prescription trends needed to satisfy elevated growth expectations.
- Wed15Apr
Actual outcome: Bull · $16.37 at outcome
Aurinia's Investor Day passed without generating significant new headlines or material updates to alter the existing narrative. In the absence of major catalysts to re-accelerate growth expectations or shift the cautious 2026 guidance, the stock remained flat and traded within its established range.
- Thu26Feb
Actual outcome: Mixed · $14.15 at outcome
Aurinia delivered a 'beat and lower' quarter, exceeding Q4 EPS and revenue estimates but providing softer-than-expected revenue guidance for 2026. While the company demonstrated sustained profitability and strong current Lupkynis sales, the cautious forward outlook signaled a potential deceleration in the drug's growth trajectory, preventing the stock from reaching bull targets and keeping it near the $13.50 bear floor.